Identification

Name
Sevoflurane
Accession Number
DB01236  (APRD00219)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

Sevoflurane (2,2,2-trifluoro-1-[trifluoromethyl]ethyl fluoromethyl ether), also called fluoromethyl, is a sweet-smelling, non-flammable, highly fluorinated methyl isopropyl ether used for induction and maintenance of general anesthesia. Together with desflurane, it is replacing isoflurane and halothane in modern anesthesiology. [Wikipedia]

Structure
Thumb
Synonyms
  • 1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
  • Sevofluran
  • Sevoflurane
  • Sevoflurano
  • Sevofluranum
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SevofluraneLiquid99.97 %Respiratory (inhalation)Baxter Laboratories2007-04-11Not applicableCanada
Sevorane AFLiquid99.97 %Respiratory (inhalation)Abbvie1995-12-31Not applicableCanada
Sojourn SevofluraneLiquid99.97 %Respiratory (inhalation)Piramal Critical Care Inc2009-11-18Not applicableCanada
UltaneLiquid250 mL/250mLRespiratory (inhalation)Abbvie1995-06-07Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SevofluraneLiquid250 mL/250mLRespiratory (inhalation)Baxter Laboratories2002-07-02Not applicableUs
SevofluraneLiquid1 mL/mLRespiratory (inhalation)Piramal Critical Care Inc2011-07-15Not applicableUs
SevofluraneLiquid250 mL/250mLRespiratory (inhalation)Sandoz2015-11-03Not applicableUs
SevofluraneLiquid250 mL/250mLRespiratory (inhalation)Baxter Laboratories2002-07-07Not applicableUs
SojournLiquid1 mL/mLRespiratory (inhalation)Piramal Critical Care Inc2010-04-13Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SevofluraneLiquid1 mL/mLRespiratory (inhalation)Halocarbon Products Corp.2007-11-19Not applicableUs
International/Other Brands
Sevorane
Categories
UNII
38LVP0K73A
CAS number
28523-86-6
Weight
Average: 200.0548
Monoisotopic: 200.007212153
Chemical Formula
C4H3F7O
InChI Key
DFEYYRMXOJXZRJ-UHFFFAOYSA-N
InChI
InChI=1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2
IUPAC Name
1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane
SMILES
FCOC(C(F)(F)F)C(F)(F)F

Pharmacology

Indication

Used for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.

Structured Indications
Not Available
Pharmacodynamics

Sevoflurane (also called fluoromethyl) is a halogenated ether used for induction and maintenance of general anesthesia. Together with desflurane, it is replacing isoflurane and halothane in modern anesthesiology. It is often administered in nitrous oxide and pure oxygen. After desflurane it is the volatile anesthetic with the fastest onset and offset. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.

Mechanism of action

Sevoflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Sevoflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase and also binds to the GABA receptor, the large conductance Ca2+ activated potassium channel, the glutamate receptor, and the glycine receptor.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
agonist
Human
AGlycine receptor subunit alpha-1
agonist
Human
AGlutamate receptor 1
antagonist
Human
APotassium voltage-gated channel subfamily A member 1
inducer
Human
ACalcium-transporting ATPase type 2C member 1
inhibitor
Human
UATP synthase subunit delta, mitochondrial
other/unknown
Human
UNADH-ubiquinone oxidoreductase chain 1
unknown
Human
AGABA-A receptor (anion channel)
positive allosteric modulator
Human
Absorption

Rapidly absorbed into circulation via the lungs, however solubility in the blood is low.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Relatively little biotransformation, only 5% is metabolized by cytochrome P450 CYP2E1 to hexafluoroisopropanol (HFIP) with release of inorganic fluoride and CO2. No other metabolic pathways have been identified for sevoflurane.

Route of elimination

The low solubility of sevoflurane facilitates rapid elimination via the lungs. In vivo metabolism studies suggest that approximately 5% of the sevoflurane dose may be metabolized. Up to 3.5% of the sevoflurane dose appears in the urine as inorganic fluoride.

Half life

15-23 hours

Clearance
Not Available
Toxicity

LC50=49881 ppm/hr (rat), LD50=10.8 g/kg (rat)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Voltage-dependent L-type calcium channel subunit alpha-1S---Not Availablec.3257G>A / c.520C>TADR InferredMalignant hyperthermia.Details
Ryanodine receptor 1---Not Availablec.103T>C / c.487C>T  … show all ADR InferredMalignant hyperthermia.Details

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Sevoflurane is combined with 7-Nitroindazole.Experimental
AbciximabSevoflurane may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolSevoflurane may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Aceprometazine.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Acetylsalicylic acid.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Sevoflurane.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Allopregnanolone.Investigational
AloxiprinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Aloxiprin.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sevoflurane.Approved, Illicit, Investigational
AlprostadilAlprostadil may increase the antiplatelet activities of Sevoflurane.Approved, Investigational
AlteplaseSevoflurane may increase the anticoagulant activities of Alteplase.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Sevoflurane.Approved, Investigational
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Sevoflurane can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amisulpride.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amobarbital.Approved, Illicit
AmperozideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amperozide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Sevoflurane.Approved, Investigational
AnagrelideSevoflurane may increase the anticoagulant activities of Anagrelide.Approved
AncrodSevoflurane may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideSevoflurane may increase the antiplatelet activities of Andrographolide.Investigational
AnistreplaseSevoflurane may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanSevoflurane may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Apixaban.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Sevoflurane.Approved, Investigational
AprepitantThe serum concentration of Sevoflurane can be increased when it is combined with Aprepitant.Approved, Investigational
ArdeparinSevoflurane may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanSevoflurane may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Sevoflurane.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sevoflurane.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sevoflurane.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Asenapine.Approved
AstaxanthinSevoflurane may increase the anticoagulant activities of Astaxanthin.Investigational
AtazanavirThe metabolism of Sevoflurane can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Sevoflurane can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Azaperone.Investigational, Vet Approved
AzelastineSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Sevoflurane.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Sevoflurane.Approved
BatroxobinSevoflurane may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminSevoflurane may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinSevoflurane may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Sevoflurane.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Sevoflurane.Approved, Withdrawn
BeraprostSevoflurane may increase the anticoagulant activities of Beraprost.Investigational
BivalirudinSevoflurane may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Sevoflurane can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Sevoflurane can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Sevoflurane can be decreased when it is combined with Bosentan.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved
BrinaseSevoflurane may increase the anticoagulant activities of Brinase.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sevoflurane.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Bromperidol.Investigational
BrotizolamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Brotizolam.Approved, Investigational, Withdrawn
BuflomedilSevoflurane may increase the antiplatelet activities of Buflomedil.Experimental
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sevoflurane.Approved, Investigational
BuprenorphineSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Sevoflurane.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sevoflurane.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Butacaine.Vet Approved
ButambenThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Sevoflurane.Approved, Illicit, Vet Approved
ButylphthalideSevoflurane may increase the antiplatelet activities of Butylphthalide.Investigational
CanertinibThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Canertinib.Investigational
CangrelorSevoflurane may increase the anticoagulant activities of Cangrelor.Approved
CaplacizumabSevoflurane may increase the anticoagulant activities of Caplacizumab.Investigational
CarbamazepineThe metabolism of Sevoflurane can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Sevoflurane.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Carfentanil.Illicit, Investigational, Vet Approved
CeritinibThe serum concentration of Sevoflurane can be increased when it is combined with Ceritinib.Approved
CertoparinSevoflurane may increase the anticoagulant activities of Certoparin.Approved, Investigational
Chloral hydrateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sevoflurane.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Sevoflurane.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Sevoflurane.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sevoflurane.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Sevoflurane.Approved, Investigational
CilostazolSevoflurane may increase the anticoagulant activities of Cilostazol.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Sevoflurane.Approved, Vet Approved
CitalopramThe metabolism of Sevoflurane can be decreased when combined with Citalopram.Approved
Citric AcidSevoflurane may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Sevoflurane can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Sevoflurane can be decreased when combined with Clemastine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Sevoflurane.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Sevoflurane is combined with clomethiazole.Investigational
ClopenthixolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clopenthixol.Experimental
ClopidogrelThe metabolism of Sevoflurane can be decreased when combined with Clopidogrel.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sevoflurane.Approved, Illicit
CloricromenSevoflurane may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneSevoflurane may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Sevoflurane can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Sevoflurane.Approved
CobicistatThe metabolism of Sevoflurane can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Sevoflurane.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Sevoflurane.Approved, Illicit
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Collagenase clostridium histolyticum.Approved, Investigational
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Sevoflurane.Approved, Investigational
CrizotinibThe metabolism of Sevoflurane can be decreased when combined with Crizotinib.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sevoflurane.Approved
CyclosporineThe metabolism of Sevoflurane can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Sevoflurane can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateSevoflurane may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Sevoflurane can be decreased when it is combined with Dabrafenib.Approved
DalteparinSevoflurane may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSevoflurane may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sevoflurane.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dapoxetine.Investigational
DarexabanSevoflurane may increase the anticoagulant activities of Darexaban.Investigational
DarunavirThe metabolism of Sevoflurane can be decreased when combined with Darunavir.Approved
DasatinibDasatinib may increase the anticoagulant activities of Sevoflurane.Approved, Investigational
DeferasiroxThe serum concentration of Sevoflurane can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideSevoflurane may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DelavirdineThe metabolism of Sevoflurane can be decreased when combined with Delavirdine.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Deoxycholic Acid.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Deramciclane.Investigational
DersalazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dersalazine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Sevoflurane.Approved
DesipramineThe metabolism of Sevoflurane can be decreased when combined with Desipramine.Approved
DesirudinSevoflurane may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseSevoflurane may increase the anticoagulant activities of Desmoteplase.Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Detomidine.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sevoflurane.Approved, Vet Approved
DextranSevoflurane may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Sevoflurane may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Sevoflurane may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Sevoflurane may increase the anticoagulant activities of Dextran 75.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sevoflurane.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Sevoflurane.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Sevoflurane.Approved, Illicit, Vet Approved
DicoumarolSevoflurane may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Diethyl ether.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Diflunisal.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Sevoflurane can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Sevoflurane can be decreased when combined with Diltiazem.Approved
DiphenadioneSevoflurane may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sevoflurane.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Sevoflurane.Approved, Illicit
DipyridamoleSevoflurane may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleSevoflurane may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DixyrazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dixyrazine.Experimental
DopamineSevoflurane may increase the arrhythmogenic activities of Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Doramectin.Vet Approved
DoxorubicinThe metabolism of Sevoflurane can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Sevoflurane can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Sevoflurane is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Illicit
DronedaroneThe metabolism of Sevoflurane can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Drotebanol.Experimental, Illicit
Drotrecogin alfaSevoflurane may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DuloxetineSevoflurane may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sevoflurane.Approved
EcgonineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ecopipam.Investigational
Edetic AcidSevoflurane may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSevoflurane may increase the anticoagulant activities of Edoxaban.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Sevoflurane.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Eltanolone.Investigational
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sevoflurane.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Sevoflurane.Approved, Investigational, Vet Approved
EnoxaparinSevoflurane may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Sevoflurane can be decreased when it is combined with Enzalutamide.Approved
EphedraSevoflurane may increase the arrhythmogenic activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineEphedrine may increase the arrhythmogenic activities of Sevoflurane.Approved
EpinastineEpinastine may increase the antiplatelet activities of Sevoflurane.Approved, Investigational
EpinephrineSevoflurane may increase the arrhythmogenic activities of Epinephrine.Approved, Vet Approved
EplivanserinSevoflurane may increase the anticoagulant activities of Eplivanserin.Investigational
eplivanserineSevoflurane may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Sevoflurane.Approved
EptifibatideSevoflurane may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
ErythromycinThe metabolism of Sevoflurane can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Sevoflurane.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sevoflurane.Approved
EthanolSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sevoflurane.Approved, Illicit, Withdrawn
Ethyl biscoumacetateSevoflurane may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Sevoflurane.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etorphine.Illicit, Vet Approved
FencamfamineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Sevoflurane.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sevoflurane.Approved, Illicit, Investigational, Vet Approved
Ferulic acidSevoflurane may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinSevoflurane may increase the anticoagulant activities of Fibrinolysin.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Sevoflurane.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Sevoflurane can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fludiazepam.Approved, Illicit
FluindioneSevoflurane may increase the anticoagulant activities of Fluindione.Investigational
FlunitrazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sevoflurane.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sevoflurane.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sevoflurane.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fluspirilene.Approved, Investigational
FluvoxamineThe metabolism of Sevoflurane can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxSevoflurane may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumSevoflurane may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormoterolSevoflurane may increase the arrhythmogenic activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Sevoflurane can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Sevoflurane can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Sevoflurane can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fospropofol.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Sevoflurane can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sevoflurane.Approved, Investigational
GabexateSevoflurane may increase the anticoagulant activities of Gabexate.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Gepirone.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Sevoflurane.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Glutethimide.Approved, Illicit
GuacetisalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Guacetisal.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Sevoflurane.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sevoflurane.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Sevoflurane.Approved, Vet Approved
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Hemoglobin crosfumaril.Experimental
HeparinSevoflurane may increase the anticoagulant activities of Heparin.Approved, Investigational
HeroinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Hexobarbital.Approved
HigenamineSevoflurane may increase the anticoagulant activities of Higenamine.Investigational
HydrocodoneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Sevoflurane.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sevoflurane.Approved, Illicit
HydroxytyrosolSevoflurane may increase the antiplatelet activities of Hydroxytyrosol.Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Sevoflurane.Approved
IbudilastSevoflurane may increase the antiplatelet activities of Ibudilast.Approved, Investigational
Icosapent ethylSevoflurane may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
IdelalisibThe metabolism of Sevoflurane can be decreased when combined with Idelalisib.Approved
IdraparinuxSevoflurane may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilSevoflurane may increase the antiplatelet activities of Ifenprodil.Approved, Investigational, Withdrawn
IfetrobanSevoflurane may increase the antiplatelet activities of Ifetroban.Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Sevoflurane.Approved, Investigational
ImatinibThe metabolism of Sevoflurane can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Sevoflurane.Investigational
IndalpineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Sevoflurane can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Indiplon.Investigational
IndobufenSevoflurane may increase the anticoagulant activities of Indobufen.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Sevoflurane.Withdrawn
IsavuconazoniumThe metabolism of Sevoflurane can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sevoflurane.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Sevoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Sevoflurane can be decreased when combined with Isoniazid.Approved
IsoprenalineSevoflurane may increase the arrhythmogenic activities of Isoprenaline.Approved
IsradipineThe metabolism of Sevoflurane can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Sevoflurane can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Sevoflurane can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Sevoflurane.Approved, Vet Approved
KetanserinSevoflurane may increase the antiplatelet activities of Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Sevoflurane can be decreased when combined with Ketoconazole.Approved, Investigational
LacidipineSevoflurane may increase the hypotensive activities of Lacidipine.Approved, Investigational
LepirudinSevoflurane may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Sevoflurane.Approved, Investigational
LetaxabanSevoflurane may increase the anticoagulant activities of Letaxaban.Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Sevoflurane.Approved, Investigational
LevodopaSevoflurane may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Sevoflurane.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Sevoflurane.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Sevoflurane.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Sevoflurane.Approved, Vet Approved
LimaprostLimaprost may increase the antiplatelet activities of Sevoflurane.Approved, Investigational
LinsidomineSevoflurane may increase the antiplatelet activities of Linsidomine.Experimental
LithiumThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Sevoflurane.Approved, Investigational
LopinavirThe metabolism of Sevoflurane can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Loprazolam.Experimental
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sevoflurane.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Sevoflurane can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Sevoflurane can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Sevoflurane.Approved
LuliconazoleThe serum concentration of Sevoflurane can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Sevoflurane can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lurasidone.Approved
MacimorelinSevoflurane may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
MebicarThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Mebicar.Experimental
MedazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Medetomidine.Vet Approved
MelagatranSevoflurane may increase the anticoagulant activities of Melagatran.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Sevoflurane.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Sevoflurane.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sevoflurane.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Meptazinol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Mesalazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sevoflurane.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Sevoflurane.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methaqualone.Illicit, Withdrawn
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Sevoflurane.Approved
MethotrimeprazineSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Sevoflurane.Approved, Investigational, Vet Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methyl salicylate.Approved, Vet Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methylecgonine.Experimental
MethylphenidateMethylphenidate may increase the hypertensive activities of Sevoflurane.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Sevoflurane.Approved
MetyrosineSevoflurane may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Sevoflurane.Approved, Illicit
MifepristoneThe serum concentration of Sevoflurane can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Milnacipran.Approved
MilrinoneMilrinone may increase the antiplatelet activities of Sevoflurane.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Investigational
MirtazapineSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Sevoflurane can be decreased when it is combined with Mitotane.Approved
MolindoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Sevoflurane.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Sevoflurane.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Investigational
NadroparinSevoflurane may increase the anticoagulant activities of Nadroparin.Approved
NafamostatSevoflurane may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilSevoflurane may increase the antiplatelet activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Sevoflurane.Approved
NefazodoneThe metabolism of Sevoflurane can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Sevoflurane can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Sevoflurane can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Sevoflurane can be increased when combined with Nevirapine.Approved
NicorandilNicorandil may increase the hypotensive activities of Sevoflurane.Approved, Investigational
NicotineThe metabolism of Sevoflurane can be decreased when combined with Nicotine.Approved
NilotinibThe metabolism of Sevoflurane can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Sevoflurane.Approved, Investigational
NimesulideSevoflurane may increase the antiplatelet activities of Nimesulide.Approved, Investigational, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sevoflurane.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sevoflurane.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nitrous oxide.Approved, Vet Approved
NorepinephrineSevoflurane may increase the arrhythmogenic activities of Norepinephrine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Normethadone.Approved, Illicit
ObinutuzumabThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Obinutuzumab.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sevoflurane.Approved, Investigational
OlaparibThe metabolism of Sevoflurane can be decreased when combined with Olaparib.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Sevoflurane.Approved, Nutraceutical
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Sevoflurane.Approved
OpiumThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Opium.Approved, Illicit
OrphenadrineSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Sevoflurane can be increased when it is combined with Osimertinib.Approved
OtamixabanSevoflurane may increase the anticoagulant activities of Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Sevoflurane.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Sevoflurane.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sevoflurane.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Sevoflurane.Approved, Investigational, Vet Approved
OzagrelSevoflurane may increase the anticoagulant activities of Ozagrel.Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sevoflurane.Approved, Vet Approved
PalbociclibThe serum concentration of Sevoflurane can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Paliperidone.Approved
ParaldehydeSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParnaparinSevoflurane may increase the anticoagulant activities of Parnaparin.Approved, Investigational
ParoxetineThe metabolism of Sevoflurane can be decreased when combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Penfluridol.Experimental
Pentaerythritol TetranitrateSevoflurane may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sevoflurane.Approved, Vet Approved
PentobarbitalThe metabolism of Sevoflurane can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Sevoflurane.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Sevoflurane.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved
PerazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Sevoflurane.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Sevoflurane.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sevoflurane.Approved
PhenibutThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Phenibut.Experimental
PhenindioneSevoflurane may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Sevoflurane can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Sevoflurane.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Phenoxyethanol.Approved
PhenprocoumonSevoflurane may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Sevoflurane.Approved
PhenytoinThe metabolism of Sevoflurane can be increased when combined with Phenytoin.Approved, Vet Approved
PicotamideSevoflurane may increase the anticoagulant activities of Picotamide.Experimental
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Sevoflurane.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pipamperone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Piritramide.Investigational
PosaconazoleThe metabolism of Sevoflurane can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleSevoflurane may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pramocaine.Approved
PrasugrelSevoflurane may increase the anticoagulant activities of Prasugrel.Approved
PrazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Sevoflurane can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Sevoflurane.Approved
PrimidoneThe metabolism of Sevoflurane can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Sevoflurane.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sevoflurane.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Sevoflurane.Approved, Vet Approved
PropanididThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Sevoflurane.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Sevoflurane.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Propoxycaine.Approved
Protein CSevoflurane may increase the anticoagulant activities of Protein C.Approved
Protein S humanSevoflurane may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSevoflurane may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Sevoflurane is combined with PSD502.Investigational
QuazepamThe serum concentration of Sevoflurane can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sevoflurane.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Raclopride.Investigational
RamatrobanSevoflurane may increase the antiplatelet activities of Ramatroban.Investigational
RanolazineThe metabolism of Sevoflurane can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sevoflurane.Approved
RelcovaptanSevoflurane may increase the antiplatelet activities of Relcovaptan.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sevoflurane.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sevoflurane.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Sevoflurane.Approved, Investigational
ResveratrolSevoflurane may increase the antiplatelet activities of Resveratrol.Approved, Experimental, Investigational
ReteplaseSevoflurane may increase the anticoagulant activities of Reteplase.Approved
ReviparinSevoflurane may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Sevoflurane.Approved
RidogrelRidogrel may increase the antiplatelet activities of Sevoflurane.Approved
RifabutinThe metabolism of Sevoflurane can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Sevoflurane can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Sevoflurane can be increased when combined with Rifapentine.Approved
RisperidoneSevoflurane may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ritanserin.Investigational
RivaroxabanSevoflurane may increase the anticoagulant activities of Rivaroxaban.Approved
RomifidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Romifidine.Vet Approved
RopiniroleSevoflurane may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sevoflurane.Approved
RosiglitazoneSevoflurane may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
RotigotineSevoflurane may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Sevoflurane can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Sevoflurane.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Sevoflurane.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Salicylic acid.Approved, Vet Approved
SaquinavirThe metabolism of Sevoflurane can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Sevoflurane can be decreased when used in combination with Sarilumab.Approved
SarpogrelateSevoflurane may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseSevoflurane may increase the anticoagulant activities of Saruplase.Experimental
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sevoflurane.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Sevoflurane.Approved, Investigational, Vet Approved
SelexipagSevoflurane may increase the anticoagulant activities of Selexipag.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sevoflurane can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Sevoflurane can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Sevoflurane can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Sevoflurane can be increased when it is combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved
SorafenibThe metabolism of Sevoflurane can be decreased when combined with Sorafenib.Approved, Investigational
SRT501Sevoflurane may increase the antiplatelet activities of SRT501.Investigational
St. John's WortThe serum concentration of Sevoflurane can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Sevoflurane can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Sevoflurane.Approved, Investigational
SulfisoxazoleThe metabolism of Sevoflurane can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideSevoflurane may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Sevoflurane.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Sultopride.Experimental
SuvorexantSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved
TelaprevirThe metabolism of Sevoflurane can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Sevoflurane can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Sevoflurane.Approved
TenecteplaseSevoflurane may increase the anticoagulant activities of Tenecteplase.Approved
TesmilifeneSevoflurane may increase the antiplatelet activities of Tesmilifene.Investigational
TetracaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tetrodotoxin.Investigational
ThalidomideSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sevoflurane.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Sevoflurane.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Thioridazine.Approved, Withdrawn
ThiotepaThe metabolism of Sevoflurane can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Thiothixene.Approved
TiaprideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tiapride.Approved, Investigational
TicagrelorSevoflurane may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineThe metabolism of Sevoflurane can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tilidine.Experimental
TinzaparinSevoflurane may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolSevoflurane may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Sevoflurane.Approved, Investigational
TirofibanSevoflurane may increase the anticoagulant activities of Tirofiban.Approved
TocilizumabThe serum concentration of Sevoflurane can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tolazoline.Approved, Vet Approved
TositumomabThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tositumomab.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Sevoflurane.Approved, Investigational
TranilastSevoflurane may increase the antiplatelet activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sevoflurane.Approved
TrapidilSevoflurane may increase the antiplatelet activities of Trapidil.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Sevoflurane.Approved, Investigational
TreprostinilSevoflurane may increase the anticoagulant activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Sevoflurane.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sevoflurane.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sevoflurane.Approved, Vet Approved
TriflusalSevoflurane may increase the anticoagulant activities of Triflusal.Approved, Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trolamine salicylate.Approved
TroxerutinSevoflurane may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseSevoflurane may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Sevoflurane.Approved, Investigational
VemurafenibThe serum concentration of Sevoflurane can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Sevoflurane can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Veralipride.Experimental
VerapamilThe metabolism of Sevoflurane can be decreased when combined with Verapamil.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Vinyl ether.Experimental
Vitamin EVitamin E may increase the antiplatelet activities of Sevoflurane.Approved, Nutraceutical, Vet Approved
VorapaxarSevoflurane may increase the anticoagulant activities of Vorapaxar.Approved
VoriconazoleThe metabolism of Sevoflurane can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Vortioxetine.Approved
WarfarinSevoflurane may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Xenon.Experimental
XimelagatranSevoflurane may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Sevoflurane.Approved, Illicit, Investigational
ZimelidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Sevoflurane can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zolazepam.Vet Approved
ZolpidemSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Sevoflurane.Approved
ZotepineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Ross C. Terrell, "Method for the preparation of sevoflurane." U.S. Patent US5969193, issued December, 1979.

US5969193
General References
Not Available
External Links
Human Metabolome Database
HMDB0015366
KEGG Drug
D00547
KEGG Compound
C07520
PubChem Compound
5206
PubChem Substance
46508591
ChemSpider
5017
ChEBI
9130
ChEMBL
CHEMBL1200694
Therapeutic Targets Database
DAP000694
PharmGKB
PA451341
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Sevoflurane
ATC Codes
N01AB08 — Sevoflurane
AHFS Codes
  • 28:04.16 — Inhalation Anesthetics
FDA label
Download (188 KB)
MSDS
Download (49.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceAnaesthesia therapy / Drug Effects1
0CompletedBasic ScienceValvular Heart Disease1
0Not Yet RecruitingPreventionColorectal Cancers1
1CompletedTreatmentInflammatory Reaction2
1RecruitingBasic ScienceAnaesthesia therapy / Renal Failure1
1RecruitingSupportive CareBalanitis / Paraphimosis / Phimosis / Postoperative pain1
1, 2CompletedDiagnosticAnaesthesia therapy1
1, 2CompletedTreatmentMyocardial Reperfusion Injury / Nonvalvular Atrial Fibrillation1
1, 2CompletedTreatmentPostoperative Cognitive Dysfunction1
1, 2CompletedTreatmentRadical Mastectomy1
1, 2Not Yet RecruitingPreventionInflammatory Lung Injury / Ischemia-Reperfusion Lung Injury / Postoperative Pulmonary Complications1
1, 2Unknown StatusTreatmentPostoperative pain1
1, 2WithdrawnOtherActive Emergence From General Anesthesia1
2CompletedNot AvailableAlcohol-Related Disorders / Opioid-Related Disorders / Substance-Related Disorders1
2CompletedDiagnosticKidney Transplant; Complications1
2CompletedSupportive CareDental Anxiety1
2CompletedSupportive CareInguinal Hernias / Undescended Testis1
2CompletedTreatmentAcute Myocardial Infarction (AMI)1
2CompletedTreatmentAdult Patients / Patients Covered by French Health Care System / Patients Who Have Given Their Consent / Requiring Sedation by Sevoflurane in ICU1
2CompletedTreatmentAnaesthesia therapy / Coronary Artery Disease1
2CompletedTreatmentBMI >30 kg/m21
2CompletedTreatmentCerebral Oxygenation1
2CompletedTreatmentDelirium1
2CompletedTreatmentTransplant; Failure, Kidney1
2CompletedTreatmentAdjunct to general anesthesia therapy1
2RecruitingSupportive CareCancer, Breast1
2RecruitingSupportive CareDown Syndrome (DS)1
2RecruitingTreatmentSubarachnoid Haemorrhage (SAH)1
2TerminatedTreatmentBrain Injury1
2Unknown StatusTreatmentAcute Kidney Injury (AKI)1
2, 3CompletedTreatmentAnaesthesia therapy1
2, 3CompletedTreatmentNewborns / Pain Measurement1
2, 3RecruitingTreatmentNeoplasms, Lung1
2, 3Unknown StatusTreatmentObesity, Morbid1
3CompletedHealth Services ResearchBaxter Anaesthesia Brand of Desflurane / Cystoscopes / Sevoflurane1
3CompletedPreventionOrthopedic Disorders1
3CompletedScreeningCoronary Arteries Disease Risk / Elevated Cardiac Risk1
3CompletedTreatmentAnaesthesia therapy1
3CompletedTreatmentAnaesthesia therapy / Craniotomy / Neurosurgery1
3CompletedTreatmentAnesthesia With Use of LMA (Laryngeal Mask Airway)1
3CompletedTreatmentAnesthetics, Inhalation / Coronary Artery Bypass Graft / Coronary Heart Disease (CHD) / Sevoflurane / Xenon1
3CompletedTreatmentCerebral Aneurysms / Cerebral Arterial Diseases1
3CompletedTreatmentCoronary Artery Bypass Graft Surgery / Coronary Artery Disease / General Anesthetic Drug Allergy1
3CompletedTreatmentEnd-stage Chronic Renal Disease / Severe Acute Kidney Failure / Transplantation, Renal1
3CompletedTreatmentMuscle Relaxation1
3Not Yet RecruitingPreventionAdjunct to general anesthesia therapy / Anaesthesia therapy / Analgesics / Analgesics, Opioid / Dexmedetomidine / Gabapentin / Ketamine / Lidocaine / Narcotics / Obstructive Sleep Apnea of Child / Oximetry, Pulse / Pathologic Processes / Physiologic Effects of Drugs / Postoperative Complications / Respiratory Depression / Sleep Disordered Breathing (SDB) / Tonsillectomy1
3RecruitingPreventionAnaesthesia therapy2
3RecruitingPreventionAdjunct to general anesthesia therapy1
3RecruitingSupportive CareFluoride Poisoning / Hepatic Function / Poisoning by Inhaled Anaesthetic / Recovery From Sedation / Renal Function1
3RecruitingSupportive CarePreoperative Sedation1
3RecruitingTreatmentAnaesthesia therapy / Child's Development / Neurotoxicity1
3Unknown StatusTreatmentIntubation, Endotracheal1
3WithdrawnPreventionCancers1
4Active Not RecruitingNot AvailableCardiac Diseases1
4Active Not RecruitingPreventionLong-Term Effects Secondary to Cancer Therapy in Adults1
4Active Not RecruitingTreatmentAnaesthesia therapy / Electroconvulsive Therapy1
4Active Not RecruitingTreatmentMyocardial Infarction (MI)1
4Active Not RecruitingTreatmentPostoperative pain1
4CompletedBasic ScienceAnaesthesia therapy / Loss of Consciousness1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedBasic ScienceSevoflurane Anesthesia1
4CompletedDiagnosticAdenotonsillectomy / Emergence Delirium / Postoperative pain1
4CompletedDiagnosticAnaesthesia therapy / Electroencephalography/ Drug Effect1
4CompletedHealth Services ResearchEmergence Agitation1
4CompletedPreventionAcute Agitation1
4CompletedPreventionAirway Complication of Anaesthesia / Healthy Volunteers1
4CompletedPreventionAnaesthesia therapy / Palonosetron / Ponv1
4CompletedPreventionAnaesthesia therapy / Surgery, Cardiac1
4CompletedPreventionCarotid Stenosis / Cerebral Arterial Aneurysm1
4CompletedPreventionCoronary Artery Disease1
4CompletedPreventionCoughing on Induction / Vapors; Inhalation1
4CompletedPreventionDelirium / Postoperative Cognitive Dysfunction / Postoperative Complications1
4CompletedPreventionDrug Usage1
4CompletedPreventionHypnotic / Specified Sedative1
4CompletedPreventionMyocardial Ischemic Reperfusion Injury1
4CompletedPreventionPostreperfusion Syndrome / Transplantation, Liver1
4CompletedSupportive CareAnaesthesia therapy / Blood Loss1
4CompletedSupportive CareCalculi / Excessive Repair / Exposure Laser / Injury of Bladder / Ureteral Stent Occlusion / Ureterostomy; Functional Disturbance / Vaginal Diseases1
4CompletedSupportive CarePostoperative pain / Prophylaxis against postoperative nausea and vomiting1
4CompletedTreatmentAbdominal / Aneurysms / Aortic Diseases / General Surgery1
4CompletedTreatmentAcute Respiratory Distress Syndrome (ARDS)1
4CompletedTreatmentAirway Reflexes, Protective / Anesthetic Recovery / Recovery After Neuromuscular Block1
4CompletedTreatmentAmbulatory Surgery / Anaesthesia therapy / Energy Expenditure / Food Intake1
4CompletedTreatmentAnaesthesia therapy1
4CompletedTreatmentAnaesthesia therapy / Electroconvulsive Therapy1
4CompletedTreatmentAnaesthesia therapy / General Surgery1
4CompletedTreatmentAnaesthetics Gases, Xenon / Anaesthetics Volatile, Sevoflurane / Depth of Anaesthesia / Prophylaxis against postoperative nausea and vomiting1
4CompletedTreatmentCarotid Stenosis1
4CompletedTreatmentClosed Fracture of Hip1
4CompletedTreatmentCoronary Artery Disease / Off Pump Coronary Artery Bypass Surgery1
4CompletedTreatmentElective Laparoscopic Surgery1
4CompletedTreatmentElectroconvulsive Therapy / Major Depressive Disorder (MDD)1
4CompletedTreatmentAdjunct to general anesthesia therapy / Generic Drugs / Sevoflurane1
4CompletedTreatmentGynecological Disease / Healthy Adults1
4CompletedTreatmentHemodynamic Stability1
4CompletedTreatmentHysteroscopic Surgery / Surgery, Laparoscopic1
4CompletedTreatmentInguinal Hernias / Undescended Testis1
4CompletedTreatmentIntracranial Aneurysms1
4CompletedTreatmentAdjunct to general anesthesia therapy / Middle Aged Patients / Sevoflurane1
4CompletedTreatmentAdjunct to general anesthesia therapy / Middle Aged Patients1
4CompletedTreatmentMuscle Relaxation1
4CompletedTreatmentMuscle Relaxation Caused by Sevoflurane1
4CompletedTreatmentMyocardial Injury1
4CompletedTreatmentMyocardial Reperfusion Injury1
4CompletedTreatmentNeoplasms, Breast1
4CompletedTreatmentPostoperative Sleep Quality1
4CompletedTreatmentPulmonary Aspiration1
4CompletedTreatmentPulmonary Resection1
4CompletedTreatmentRetinal Disorders1
4Enrolling by InvitationPreventionAnesthesia, Intratracheal / Hernia / Intravenous Anesthesia / Pain, Acute / Pain, Chronic1
4Enrolling by InvitationSupportive CareSmooth muscle relaxation prior to radiological procedures1
4Not Yet RecruitingDiagnosticGlycogen Synthase Kinase 31
4Not Yet RecruitingTreatmentDelirium1
4Not Yet RecruitingTreatmentGynecology / Surgery, Laparoscopic1
4Not Yet RecruitingTreatmentPost-transplantation Liver Allograft Function1
4RecruitingBasic ScienceConsciousness / Loss of Consciousness1
4RecruitingDiagnosticAnesthesia; Adverse Effect / Laryngeal Masks / Respiratory System Abnormalities1
4RecruitingDiagnosticOxygen Saturation1
4RecruitingPreventionAcute Kidney Injury (AKI) / Anaesthesia therapy1
4RecruitingPreventionAnaesthesia therapy1
4RecruitingPreventionCholangiocarcinomas / Gallbladder Neoplasms / Hepatocellular,Carcinoma1
4RecruitingPreventionEndovascular Repair of Aortic Aneurysm / Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities1
4RecruitingPreventionIntra-abdominal and Intrapelvic Surgery / Intra-abdominal Surgery1
4RecruitingPreventionPostoperative Cognitive Dysfunction1
4RecruitingPreventionSleep Apnea Syndromes / Sleep Apnea, Obstructive1
4RecruitingPreventionVascular Surgery1
4RecruitingSupportive CareAnesthesia, Conduction / Drug Interactions1
4RecruitingSupportive CareBehaviors / Cognitive Change1
4RecruitingSupportive CareColonic Neoplasms / Neoplasms, Breast / Rectal Neoplasms1
4RecruitingTreatmentAcute Rejection in Kidney Transplantation / Delayed Graft Function / Renal Outcome After Kidney Transplantation1
4RecruitingTreatmentAdvanced Chronic Rhinosinusitis1
4RecruitingTreatmentAmnestic / Cognitive Disorders / Delirium / Dementias1
4RecruitingTreatmentAnaesthesia therapy / Delirium / Hip Fractures1
4RecruitingTreatmentAnesthetic Complication Spinal / Microcirculation1
4RecruitingTreatmentCesarean Section / Propofol / Sevoflurane1
4RecruitingTreatmentCoronary Artery Bypass Graft / Coronary Artery Bypass Grafting (CABG) Surgery / Surgery, Cardiac1
4RecruitingTreatmentFemale Breast Carcinoma1
4RecruitingTreatmentOxygenation During One Lung Ventilation1
4RecruitingTreatmentPost-operative Residual Curarization1
4TerminatedDiagnosticVentricular Dysfunction / Young Healthy Adults1
4TerminatedPreventionDelirium on Emergence1
4TerminatedPreventionLaryngospasm1
4TerminatedTreatmentArterial Hypotension1
4Unknown StatusDiagnosticCognitive Impairments1
4Unknown StatusPreventionAnaesthetic Preconditioning / Myocardial Injury1
4Unknown StatusPreventionCerebral Hypoxia / Postoperative Delirium1
4Unknown StatusPreventionCoronary Artery Bypass Surgery1
4Unknown StatusPreventionAdjunct to general anesthesia therapy / Geriatric Patients1
4Unknown StatusSupportive CarePectus Excavatum1
4Unknown StatusTreatmentAnaesthesia therapy / Hemodynamics / Oxidative Stress1
4Unknown StatusTreatmentBispectral Index / Etomidate / Induction / Pediatric1
4Unknown StatusTreatmentDepressive Disorders1
4Unknown StatusTreatmentEmergence Agitation1
4Unknown StatusTreatmentHaemodynamic Rebound1
4Unknown StatusTreatmentHyperalgesia1
4Unknown StatusTreatmentIschemia/Reperfusion Injury1
4WithdrawnPreventionMemory Disorders / Other Functional Disturbances Following Cardiac Surgery1
Not AvailableCompletedNot AvailableAirway Management During Operative Procedure1
Not AvailableCompletedNot AvailableAnaesthesia1
Not AvailableCompletedNot AvailableAnaesthesia therapy1
Not AvailableCompletedNot AvailableAnaesthesia therapy / Effects of Dexmedetomidine / Elderly Patients / Emergence From Anesthesia / Recovery From Anesthesia1
Not AvailableCompletedNot AvailableAnaesthesia therapy / General Surgery1
Not AvailableCompletedNot AvailableBiliary Atresia1
Not AvailableCompletedNot AvailableBlindness1
Not AvailableCompletedNot AvailableCardioprotection / Hepatic Function / Recovery From Sedation / Renal Function / Sevoflurane Consumption1
Not AvailableCompletedNot AvailableLiver Dysfunction1
Not AvailableCompletedNot AvailableNephrectomy,Kidney Donation1
Not AvailableCompletedNot AvailableOpioid-Related Disorders / Substance-Related Disorders1
Not AvailableCompletedNot AvailableRhytidoplasty1
Not AvailableCompletedNot AvailableRotator Cuff Tear Arthropathy1
Not AvailableCompletedNot AvailableAdjunct to general anesthesia therapy1
Not AvailableCompletedBasic ScienceDrug Interaction Potentiation1
Not AvailableCompletedBasic ScienceHyperglycemias1
Not AvailableCompletedBasic SciencePharmacokinetics of Inhaled Anesthetics1
Not AvailableCompletedBasic ScienceAdjunct to general anesthesia therapy1
Not AvailableCompletedDiagnosticPostoperative Cognitive Dysfunction1
Not AvailableCompletedHealth Services ResearchDelayed Recovery From Anaesthesia1
Not AvailableCompletedOtherEntropion1
Not AvailableCompletedPreventionAmbulation Difficulty / Children / Urologic Diseases1
Not AvailableCompletedPreventionAnaesthesia therapy1
Not AvailableCompletedPreventionAnaesthesia therapy / Catheter Site Discomfort / Complications / Urinary Bladder Neoplasms2
Not AvailableCompletedPreventionCancer, Breast1
Not AvailableCompletedPreventionDelirium on Emergence1
Not AvailableCompletedPreventionDesflurane Anesthesia1
Not AvailableCompletedPreventionEnd-stage Liver Disease (ESLD)1
Not AvailableCompletedPreventionGeneral Surgery / Prostate Cancer1
Not AvailableCompletedPreventionHigh Sensitive Troponin T Release1
Not AvailableCompletedPreventionLaryngeal Injuries1
Not AvailableCompletedPreventionReperfusion Injury1
Not AvailableCompletedPreventionSurgery, Cardiac1
Not AvailableCompletedPreventionThoracic Surgery With One-lung Ventilation1
Not AvailableCompletedPreventionVocal Cord; Injury, Superficial1
Not AvailableCompletedSupportive CareAirway Complications1
Not AvailableCompletedSupportive CareAnesthesia; Reaction1
Not AvailableCompletedSupportive CareCataracts / Corneal Inflammation / Pterygium / Retina Detachment / Vitreous Hemorrhage1
Not AvailableCompletedSupportive CareEndarterectomy / Postoperative Cognitive Dysfunction1
Not AvailableCompletedSupportive CareMyocardial Ischemia1
Not AvailableCompletedTreatmentAnaesthesia therapy / Bispectral Index Monitoring / Delirium / Dementias1
Not AvailableCompletedTreatmentAnaesthesia therapy / Immunotoxicity / Inert Gas Narcosis1
Not AvailableCompletedTreatmentBlood Loss1
Not AvailableCompletedTreatmentCardiac On-pump Surgery1
Not AvailableCompletedTreatmentCerebral Palsy (CP) / Postoperative pain1
Not AvailableCompletedTreatmentEar Deformities, Acquired1
Not AvailableCompletedTreatmentEmergence Delirium1
Not AvailableCompletedTreatmentHepatectomy1
Not AvailableCompletedTreatmentMicrovascular Breast Flap in Plastic Surgery1
Not AvailableCompletedTreatmentOpioid-Related Disorders / Substance-Related Disorders1
Not AvailableCompletedTreatmentPostoperative pain3
Not AvailableCompletedTreatmentPregnancy Termination / Uterine Curettage1
Not AvailableCompletedTreatmentAdjunct to general anesthesia therapy1
Not AvailableEnrolling by InvitationNot AvailableBrain Diseases / Cardiovascular Disease (CVD) / Central Nervous System Diseases / Cerebrovascular Disorders / Cerebrovascular Stroke / Ischemia, Brain / Nervous System Diseases / Strokes / Vascular Diseases1
Not AvailableEnrolling by InvitationPreventionChildren / Transplantation, Liver1
Not AvailableNot Yet RecruitingNot AvailableHyperperfusion Syndrome / Moyamoya Disease1
Not AvailableNot Yet RecruitingNot AvailableSex / TOF1
Not AvailableNot Yet RecruitingBasic ScienceLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableNot Yet RecruitingPreventionHip Arthroplasty1
Not AvailableNot Yet RecruitingSupportive CareCardiovascular Disease (CVD)1
Not AvailableNot Yet RecruitingSupportive CareFemale Breast Cancer1
Not AvailableNot Yet RecruitingSupportive CareNeoplasms, Brain1
Not AvailableNot Yet RecruitingTreatmentBlood Loss,Surgical / Blood Transfusions1
Not AvailableNot Yet RecruitingTreatmentPostoperative Recovery / Transurethral Resection of the Bladder / Urinary Bladder Neoplasms1
Not AvailableRecruitingNot AvailableAnesthetics, Inhalation1
Not AvailableRecruitingNot AvailableCardiovascular Surgical Procedures1
Not AvailableRecruitingNot AvailableGeneral Anesthetics Toxicity / Lymphocyte Destruction / Metastatic Colorectal Cancers / Molecular Mechanism of Pharmacological Action / Survival Rate1
Not AvailableRecruitingNot AvailableInflammatory Responses1
Not AvailableRecruitingNot AvailableInhalation and Intravenous Anesthesia / Microcirculatory Effects of Anesthesia1
Not AvailableRecruitingNot AvailablePituitary Adenomas1
Not AvailableRecruitingNot AvailablePropofol / Sevoflurane1
Not AvailableRecruitingBasic ScienceCancer, Breast2
Not AvailableRecruitingBasic ScienceMalignant Neoplasm of Colon1
Not AvailableRecruitingDiagnosticVentricular Tachycardia (VT)1
Not AvailableRecruitingOtherGeneral Surgery1
Not AvailableRecruitingOtherMitochondrial Diseases1
Not AvailableRecruitingPreventionArterial Hypotension1
Not AvailableRecruitingPreventionCognitive Impairment, Mild1
Not AvailableRecruitingPreventionHyperglycemia Stress1
Not AvailableRecruitingPreventionIntubation; Difficult or Failed1
Not AvailableRecruitingPreventionMyocardial Ischemia1
Not AvailableRecruitingPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableRecruitingSupportive CareInguinal Hernias / Postoperative pain1
Not AvailableRecruitingSupportive CarePostoperative pain / Undescended Testis1
Not AvailableRecruitingSupportive CareRenal Transplant Recipient Patients1
Not AvailableRecruitingTreatmentAnaesthesia therapy / Children / Pain1
Not AvailableRecruitingTreatmentCardiac Arrest / Therapeutic Hypothermia1
Not AvailableRecruitingTreatmentCongenital Heart Disease (CHD) / Infant, Premature, Diseases1
Not AvailableRecruitingTreatmentMyocardial Infarction (MI)1
Not AvailableRecruitingTreatmentNonvalvular Atrial Fibrillation1
Not AvailableRecruitingTreatmentSepsis1
Not AvailableTerminatedNot AvailableAnaesthesia therapy1
Not AvailableTerminatedPreventionPostoperative pain / Varicosities of the great saphenous vein1
Not AvailableTerminatedSupportive CareMitochondrial Diseases1
Not AvailableTerminatedTreatmentChronic Rhinosinusitis1
Not AvailableUnknown StatusNot AvailableIOP Changes Due to Anesthesia (Healthy Patients)1
Not AvailableUnknown StatusNot AvailableLung Cancers / Neoplasms, Lung1
Not AvailableUnknown StatusHealth Services ResearchDuration of Hospitalization1
Not AvailableUnknown StatusScreeningAnesthesia Recovery Period / Delirium, Dementia, Cognitive Disorders / Mental Competency / Neurobehavioural Manifestation1
Not AvailableUnknown StatusSupportive CareAdjunct to general anesthesia therapy1
Not AvailableUnknown StatusTreatmentCongenital Heart Disease (CHD)1
Not AvailableUnknown StatusTreatmentArterial hypoxia1
Not AvailableWithdrawnPreventionNeoplasms, Brain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
LiquidRespiratory (inhalation)99.97 %
LiquidRespiratory (inhalation)1 mL/mL
LiquidRespiratory (inhalation)250 mL/250mL
Prices
Unit descriptionCostUnit
Ultane 250 ml pen bottle1.16USD ml
Sojourn inhalation liquid0.99USD ml
Sevoflurane inhalation liquid0.89USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6288127Yes1997-07-272017-07-27Us
US5990176Yes1997-07-272017-07-27Us
US6074668Yes1998-07-092018-07-09Us
US6444859Yes1997-07-272017-07-27Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)< 25 °CPhysProp
boiling point (°C)58.5 °CPhysProp
water solubilityVery slightly solubleNot Available
logP2.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.48 mg/mLALOGPS
logP2.44ALOGPS
logP2.27ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)15.07ChemAxon
pKa (Strongest Basic)-4.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.23 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity23.3 m3·mol-1ChemAxon
Polarizability9.83 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9963
Blood Brain Barrier+0.9941
Caco-2 permeable+0.6134
P-glycoprotein substrateNon-substrate0.8839
P-glycoprotein inhibitor INon-inhibitor0.8807
P-glycoprotein inhibitor IINon-inhibitor0.5436
Renal organic cation transporterNon-inhibitor0.8649
CYP450 2C9 substrateNon-substrate0.9039
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6876
CYP450 1A2 substrateInhibitor0.5254
CYP450 2C9 inhibitorNon-inhibitor0.7941
CYP450 2D6 inhibitorNon-inhibitor0.9114
CYP450 2C19 inhibitorInhibitor0.5569
CYP450 3A4 inhibitorNon-inhibitor0.9148
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7006
Ames testAMES toxic0.5082
CarcinogenicityCarcinogens 0.7014
BiodegradationNot ready biodegradable0.8564
Rat acute toxicity1.3361 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9485
hERG inhibition (predictor II)Non-inhibitor0.8685
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dialkyl ethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are alkyl groups.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Ethers
Direct Parent
Dialkyl ethers
Alternative Parents
Organofluorides / Hydrocarbon derivatives / Alkyl fluorides
Substituents
Dialkyl ether / Hydrocarbon derivative / Organofluoride / Organohalogen compound / Alkyl halide / Alkyl fluoride / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
organofluorine compound, ether (CHEBI:9130)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Transmitter-gated ion channel activity
Specific Function
The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).
Gene Name
GLRA1
Uniprot ID
P23415
Uniprot Name
Glycine receptor subunit alpha-1
Molecular Weight
52623.35 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Pdz domain binding
Specific Function
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a co...
Gene Name
GRIA1
Uniprot ID
P42261
Uniprot Name
Glutamate receptor 1
Molecular Weight
101505.245 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inducer
General Function
Voltage-gated potassium channel activity
Specific Function
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:1990381...
Gene Name
KCNA1
Uniprot ID
Q09470
Uniprot Name
Potassium voltage-gated channel subfamily A member 1
Molecular Weight
56465.01 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Signal transducer activity
Specific Function
This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the transport of the calcium.
Gene Name
ATP2C1
Uniprot ID
P98194
Uniprot Name
Calcium-transporting ATPase type 2C member 1
Molecular Weight
100576.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Transporter activity
Specific Function
Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport comp...
Gene Name
ATP5D
Uniprot ID
P30049
Uniprot Name
ATP synthase subunit delta, mitochondrial
Molecular Weight
17489.755 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Unknown
General Function
Nadh dehydrogenase (ubiquinone) activity
Specific Function
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the tra...
Gene Name
MT-ND1
Uniprot ID
P03886
Uniprot Name
NADH-ubiquinone oxidoreductase chain 1
Molecular Weight
35660.055 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Sawas AH, Pentyala SN, Rebecchi MJ: Binding of volatile anesthetics to serum albumin: measurements of enthalpy and solvent contributions. Biochemistry. 2004 Oct 5;43(39):12675-85. [PubMed:15449957]

Drug created on June 13, 2005 07:24 / Updated on January 19, 2018 10:55